Physician profile
Matthew Kaw
NPI 1821044819
$2,623.25
in general payments reported to CMS, 2019-2025
24 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $260 · 2021: $506 · 2022: $314 · 2023: $199 · 2024: $180 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $706.52 | 2019-2022 | |
| Amgen INC. | $221.90 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $218.35 | 2019-2025 | |
| Lilly USA, LLC | $216.32 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $162.82 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.91 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $120.05 | 2019-2021 | |
| Amarin Pharma, INC. | $115.95 | 2019-2021 | |
| Abbvie INC. | $95.29 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.77 | 2022-2025 | Jardiance |
| Cranial Technologies, INC | $76.93 | 2021-2024 | Doc Band |
| Ardelyx, INC. | $75.38 | 2025 | Ibsrela |
| Allergan, INC. | $66.87 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $66.46 | 2019-2025 | Breztri |
| Almatica Pharma LLC | $65.83 | 2023 | Loreev Xr, Gralise |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.93 | 2023-2025 | |
| Avanir Pharmaceuticals, INC. | $22.15 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.33 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $19.85 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $18.26 | 2025 | Arexvy, Shingrix |
| Scilex Pharmaceuticals INC. | $14.80 | 2025 | |
| Shield Therapeutics INC | $14.32 | 2024 | |
| Ironwood Pharmaceuticals, INC | $13.38 | 2023 | Linzess |
| Horizon Therapeutics Plc | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.